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Long-lived memory T cells are able to persist in the host in the absence of antigen; however, the mechanism 
by which they are maintained is not well understood. Recently, a subset of human T cells, stem cell memory T 
cells (TSCM cells), was shown to be self-renewing and multipotent, thereby providing a potential reservoir for 
T cell memory throughout life. However, their in vivo dynamics and homeostasis still remain to be defined 
due to the lack of suitable animal models. We identified T cells with a TSCM phenotype and stem cell–like 
properties in nonhuman primates. These cells were the least-differentiated memory subset, were functionally 
distinct from conventional memory cells, and served as precursors of central memory. Antigen-specific TSCM 
cells preferentially localized to LNs and were virtually absent from mucosal surfaces. They were generated in 
the acute phase of viral infection, preferentially survived in comparison with all other memory cells follow-
ing elimination of antigen, and stably persisted for the long term. Thus, one mechanism for maintenance of 
long-term T cell memory derives from the unique homeostatic properties of TSCM cells. Vaccination strategies 
designed to elicit durable cellular immunity should target the generation of TSCM cells.
Introduction
Long-lived memory T cells are able to persist in the host in the 
absence of antigen (1). In mice, lymphocytic choriomeningitis 
virus–specific CD8+ T cells are maintained for life after the acute 
infection (2). Similarly, in humans, vaccinia virus–specific T cells 
can be found for many decades after vaccination (3). However, it is 
unclear whether these memory cells are long lived per se, or differ-
entiate regularly from a rarer, long-lived antigen-specific precursor 
population undergoing slow homeostatic turnover (4).
Dozens of subsets form the memory T cell compartment (5). 
Conventionally, antigen-experienced T cells have been divided 
into central memory (TCM) cells and effector memory (TEM) 
cells, according to their phenotype, function, differentiation 
history, and anatomical localization (6). Previously, TCM cells as 
a whole were thought to exhibit stem cell–like behavior, given 
their capacity to self-renew and to generate more differentiated 
progeny in response to multiple stimuli (7). However, this con-
cept was recently challenged by the discovery of an earlier stage 
of memory T cell differentiation in humans, termed T stem cell 
memory (TSCM) (8). TSCM cells are precursors of other memory 
cells including TCM cells, and display enhanced self-renewal 
capacity; TSCM cells can also generate multiple subsets of mem-
ory cells in vitro, and, despite sharing multiple functional attrib-
utes with conventional memory cells, they maintain a largely 
naive-like phenotype, with a core of expressed genes charac-
teristic of naive cells (8). To date, mouse TSCM cells have been 
described (9, 10), but those specific for viral or tumor antigens 
have not been identified, making their relevance in physiology 
and pathology elusive. To address these questions in a relevant 
animal model, we attempted to characterize TSCM cells (either as 
a bulk population or antigen-specific) in healthy nonhuman pri-
mates (NHPs) and during the course of SIV infection. The iden-
tification of such a population in the NHPs, the most widely 
used animal model for HIV infection, is directly relevant to the 
design of an effective HIV vaccine.
Results and Discussion
Human CD8+ TSCM cells display a largely naive-like phenotype, but 
express high levels of CD95, CXCR3, CD122, and LFA-1 (8, 11). 
In order to characterize the role of TSCM cells in the generation of 
T cell memory in vivo, we sought to determine whether a similar 
subset of cells exists in NHPs. In both healthy rhesus macaques 
(RMs) and pigtail macaques (PTMs), we identified CD95hi CD8+ 
T cells in the CD45RA+CCR7+CD27+CD28+IL-7Rα+ naive-like 
compartment (Figure 1A). Similarly to those in humans, NHP 
TSCM cells constitute about 2%–3% of circulating CD8+ T cells (Fig-
ure 1B). We also identified a CD4+ TSCM subset in PBMCs, with a 
phenotype and frequency similar to CD8+ TSCM cells (Supplemen-
tal Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI66327DS1). The NHP model allows a 
detailed examination of cellular distributions in tissues; we found 
that CD8+ TSCM cells from healthy RMs are most abundant in LNs, 
less so in the spleen and bone marrow, and are virtually absent at 
mucosal surfaces, i.e., the jejunum, the rectum, and the BAL, where 
only TCM and TEM cells are present (Figure 1C). CD4+ TSCM cells 
displayed a similar distribution in the body, although less skewed 
toward the LNs (Supplemental Figure 1C). Thus, TSCM cells have a 
tropism for secondary lymphoid tissues, with a distribution most 
similar to naive T (TN) cells.
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We next investigated whether NHP TSCM cells have features of 
memory cells and precede TCM and TEM cells in terms of differ-
entiation. Immunophenotypic analysis of activation and memory 
markers (8) indicated that NHP CD8+ TSCM cells from healthy RMs 
are a discrete subset (Figure 2, A and B). Indeed, they are interme-
diate between TN and TCM cells, according to the expression of pro-
teins that are progressively upregulated (CCR5, IL-18Rα) or down-
regulated (CD38, CD130) with differentiation (Figure 2B). The 
human TSCM core phenotypic markers CXCR3, CD122 (Figure 2, 
A and B), and LFA-1 (Supplemental Figure 2, A and B) were also 
upregulated in TSCM cells compared with TN cells. Unexpectedly, a 
relatively large proportion of TSCM cells were proliferating (Ki-67+) 
in the PBMCs (Figure 2A), but not in the LNs, spleen, or BM (Sup-
plemental Figure 2C). In all sites, TSCM cells were mostly HLA-DR 
negative. Similar phenotypic data were obtained for CD4+ TSCM 
cells (Supplemental Figure 1D).
To assess the cytokine production capability of NHP TSCM cells, 
we stimulated PBMCs from healthy RMs with staphylococcal 
enterotoxin B (SEB). Following stimulation, all subsets of memory 
T cells produced IFN-γ, TNF, and IL-2 (Figure 2C). The patterns 
of cytokine expression show that TSCM cells differ from TCM and 
TEM cells, with a decreased proportion of cells producing a com-
bination of IL-2 and TNF, but not IFN-γ, and an increased pro-
portion of cells producing IFN-γ and IL-2 or IFN-γ only. Overall, 
their quality of cytokine production differed from conventional 
memory T cells (Figure 2C). TSCM cells also display attributes of 
memory in vivo, as proliferating (Ki-67+) TSCM cells incorporated 
BrdU following SIVmac239 infection in PTMs similarly to conven-
tional TCM and TEM cells (Supplemental Figure 2D). In contrast, 
BrdU incorporation by TN cells was negligible.
To further assess whether TSCM cells from healthy RMs constitute 
discrete, less-differentiated memory cells, we evaluated their multi-
potency (i.e., to generate other subsets) and self-renewing capability 
(i.e., to maintain a TSCM phenotype) in response to TCR stimulation 
in vitro with αCD3/CD28 antibodies (Figure 2D). In the prolifer-
ating (CFSE-diluted) fraction, TSCM phenotype cells could only be 
recovered from sort-purified TN or TSCM cells. In addition, TSCM cells 
were also able to generate cells with a TCM, TEM, and terminal effector 
T (TTE) phenotype (Figure 2D). Importantly, TCM cells could not gen-
erate TSCM cells, but did generate TCM and TEM cells. Together, these 
data indicate that TSCM cells constitute a discrete memory subset 
and support the concept that TSCM cells serve as precursors of other 
memory cells, according to the relationship TSCM→TCM→TEM→TTE.
To determine the dynamics of antigen-specific T cell subsets 
during a natural infection in vivo, we enumerated SIV-specific 
CD8+ T cells in RMs using Mamu-A*01 pMHCI multimers 
Figure 1
Identiication of CD8+ TSCM cells in healthy macaques. (A) Flow cytometric analysis of PBMCs from a healthy human donor, an RM, and a PTM. 
Plots show live CD3+CD8+CD4– lymphocytes. (B) Mean ± SEM percentage of CD8+ TN, TSCM, TCM, and TEM cells in the peripheral blood (PB) of 
RMs (n = 6). (C) As in B, but in different organs. Data indicate the proportion relative to PB (dashed bar). Data in B and C are expressed in log 
scale. MLN, mesenteric LN; ALN, axillary LN; ILN, inguinal LN; Spl, spleen; Jej, jejunum; Rect, rectum.
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presenting SIV-derived Gag CM9 or Tat-TL8 peptides (Supple-
mental Figure 3A). Antigen-specific TSCM cells were detected 
within both CM9- and TL8-specific cells at day 21 after infection, 
thus demonstrating that they are elicited early (Figure 3A). The 
antigen-specific TSCM cells were not merely “bystander” cells, 
but displayed evidence of activation (HLA-DR+, CD38bright) and 
proliferation (Ki-67+) (Supplemental Figure 3B). At day 21 after 
infection, CM9- and TL8-specific CD8+ T cells were dominated by 
TEM-like cells, while TSCM, TCM, and TTE cells constituted a small 
proportion of the total response (Figure 3, A and B).
The biology of the CM9 and TL8 Mamu-A*01–restricted 
epitopes is highly divergent. Unlike CM9, which is generally main-
tained intact throughout the chronic phase of infection, the TL8 
uniformly undergoes escape mutation within 4–5 weeks after 
SIVmac239 or SIVmac251 infection in 100% of animals (12–14). Tat-
TL8 sequence variants do not stimulate TL8-specific T cells due 
to their reduced capability to bind the pMamu-A*01 class I mole-
cule (12) or to signal through the TCR (14). Following TL8 escape, 
there is at least a 105-fold decrease in the relative antigen load of 
TL8 versus CM9. Using this model, it is thus possible to investigate 
the relative antigen dependence of the different T cell subsets. As 
expected, viral escape from TL8-directed CTLs resulted in a dra-
matic decrease in the frequency of total circulating TL8-specific 
CD8+ T cells between days 21 and 70–120 after infection (Supple-
mental Figure 3C). Conversely, CM9-specific CD8+ T cells were 
maintained at high levels throughout the course of the infection 
(Supplemental Figure 3C). Notably, despite the near-complete 
elimination of antigen (extremely low levels from residual “archi-
val,” unmutated virus may persist) (12), TL8-specific CD8+ T cells 
did not disappear, but remained detectable beyond day 335 after 
infection (Supplemental Figure 3C).
Phenotypic analysis of the TL8-specific population revealed 
a significant difference in the dynamics of memory subsets in 
response to viral escape mutation. Indeed, the proportion of 
TL8-specific TEM cells decreased dramatically in favor of the less 
differentiated TSCM and TCM cells (Figure 3, A and B). By day 
70 after infection, TSCM cells constituted approximately 25% of 
the total TL8-specific response (Figure 3B). In contrast, mem-
ory subset distribution within the CM9-specific CD8+ T cells 
remained unchanged between days 21 and 70 after infection 
Figure 2
TSCM cells from healthy RMs are phenotypically and functionally distinct T cells. (A) Expression of CXCR3 and CD122 on CD8+ TN, TSCM, TCM, 
and TEM cells by low cytometry. (B) Percentage of CD8+ T cell subsets expressing CCR5, IL-18Rα, CD38, Ki-67, HLA-DR, or CXCR3. CD130 and 
CD122 are indicated as MFI. *P < 0.05 versus TSCM. (C) Pie charts representing the proportion of cells producing different combinations of IL-2, 
IFN-γ, and TNF after SEB stimulation. *P < 0.05,  ***P < 0.001. (D) Mean percentage of cells with various differentiation phenotypes recovered 
following activation of FACS-sorted TN, TSCM, TCM, and TEM cells by αCD3/CD28 antibodies in vitro for 5 days (n = 6). The analysis was carried out 
on cells that diluted CFSE. Boxes in B and D show interquartile range and median values.
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(Figure 3B). Furthermore, as would be expected from a loss of 
antigen, TL8-specific, but not CM9-specific TSCM and TCM cells, 
became quiescent (Ki-67–, HLA-DR–) at day 70 after infection 
(Supplemental Figure 3B).
Following antigen loss, TL8-specific TCM and TEM cells under-
went considerable attrition (respectively, ~10- and ~100-fold 
decrease in the absolute count at day 70 versus day 14), while 
TSCM cells did not (Figure 3C and Supplemental Figure 3D). Sim-
ilarly, CM9-specific TSCM counts did not change over time, while 
the CM9-specific TCM and TEM cells contracted, albeit at markedly 
slower rates compared with TL8-specific CD8+ T cells (Supple-
mental Figure 3D), reflecting the 1-log decrease in viral load fol-
lowing peak viremia by day 70 after infection (i.e., establishment 
of the viral set point).
CM9- and TL8-specific subsets, FACS-sorted from a chroni-
cally SIV-infected RM, were fully functional as they proliferated 
following cognate peptide stimulation in vitro (Supplemental 
Figure 4A). Importantly, each T cell subset regenerated cells 
with the same phenotype and simultaneously derived more, 
not less, differentiated progeny according to the relationship 
TSCM→TCM→TEM (Supplemental Figure 4B), thus recapitulating 
the results depicted in Figure 2D and further demonstrating the 
multipotency and self-renewing capability of TSCM cells in vitro. 
The distribution of memory subsets observed at day 70 after 
infection within both the CM9- and TL8-specific populations 
was similar in 4 animals at more than 335 days after infection 
(Supplemental Figure 5A).
Following escape mutation of the TL8 epitope, the frequency 
of SIV-specific T cell subsets did not change in the inguinal LNs 
over time in 2 animals, suggesting that their lymphoid localiza-
tion is not time dependent (Supplemental Figure 5B). Moreover, 
the same cells maintained a stable pattern of localization, as 
described in Figure 1C, during late chronic infection (Supple-
mental Figure 5C). Collectively, these findings indicate that TSCM 
cells are stable, long-lived memory cells with enhanced survival 
capacity compared with conventional memory cells when little or 
no antigen is present.
Freshly isolated CM9-specific TSCM cells were indeed less proapop-
totic in vitro than TCM and TEM cells during chronic infection (Sup-
plemental Figure 6, A and B). Similarly, fewer TL8-specific TSCM cells 
Figure 3
Preferential maintenance of TSCM cells following escape of the cognate antigen. (A) Tetramer+CD8+ T cells (black) superimposed on total CD8+ T 
cells (gray) at day 21 and day 120 after infection with SIVmac251. Gates irst identify CD45RA+CCR7+ cells, then CD28+CD95+ TSCM cells. Numbers 
in the CD28 versus CD95 plots indicate the percentage of TSCM cells out of total antigen-speciic (tetramer+) T cells. (B) Pie charts depicting the 
proportion of CM9- and TL8-speciic CD8+ T cells with different phenotypes (TSCM: CD45RA+CCR7+CD28+CD95+; TCM: CD45RA–CCR7+; TEM: 
CD45RA–CCR7–; TTE: CD45RA+CCR7–) at day 21 and day 70 after infection (n = 6). **P < 0.01. (C) Fold change in the absolute count of SIV-speciic 
CD8+ T cells between day 21 and day 70 after infection (n = 4). Red bars indicate median values. Data are expressed in log scale. p.i., post infection.
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(AAALAC) and meet NIH standards (Guide for the Care and Use of Labora-
tory Animals. NIH publication no. 85-23. Revised 1985). See Supplemental 
Methods for animal procedures.
Antibodies, Mamu-A*01 tetramers, and flow cytometry. Surface and 
intracellular analysis of protein expression and cytokine production was 
performed as described (8, 18). Tetramer staining was conducted at 37°C 
for 10 minutes. Cells were analyzed and sorted using a modified LSR II and 
FACSAria II, respectively (BD Biosciences).
Apoptosis studies. Fresh PBMCs were cultured in complete RPMI 1640 
medium supplemented with αCD49d and αCD28 antibodies (both at 1 μg/ml; 
BD Biosciences) at 37°C for 42 hours. Surface phosphatidylserine expres-
sion was revealed as described (18).
Proliferation studies. Cell proliferation was determined by dilution of CFSE 
(Life Technologies) as described (8). Labeled cells were stimulated for 6 days 
with 2 μg/ml CM9 and TL8 peptides in the presence of sorted, CD3– 
autologous antigen-presenting cells (1:1 ratio to T cells) or with plate-
bound αCD3 (10 μg/ml; clone FN18) plus soluble αCD28 (1 μg/ml; clone 
CD28.2) antibodies.
In vivo BrdU labeling. Administration of BrdU (Sigma-Aldrich) and analy-
sis of its incorporation were performed as described (18).
Gene expression analysis. CD8+ T cell subsets were sorted as depicted in 
Supplemental Figure 7. See Supplemental Methods for gene expression 
quantification procedures.
Statistics. Analyses were performed using Prism (GraphPad Software Inc.), 
JMP (SAS Institute Inc.), and SPICE (NIAID, NIH) (19). Nonparametric 
Wilcoxon rank tests were used to compare distributions. When possible, 
a paired Student’s t test (2 tailed) was used. In some cases, nonparametric 
1-way ANOVA (Kruskal-Wallis test) was used to compare 3 or more groups. 
Distributions shown with pie charts were compared with SPICE. P values 
were considered significant when less than 0.05.
Study approval. All animal procedures were reviewed and approved by the 
Institutional Animal Care and Usage Committee of the VRC, the NIAID, 
the NCI, and Oregon Health and Science University (Portland, Oregon, 
USA). The anonymous human blood sample (Figure 1A) was obtained 
from the NIH blood bank under institutional review board exemption.
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bound annexin V compared with the total memory fraction (there 
were insufficient T cells for evaluation of TL8-specific TCM and TEM 
cells individually; Supplemental Figure 6B). Consistent with the 
lack of chronic antigen exposure, TL8-specific cells were less pro-
apoptotic than CM9-specific cells (Supplemental Figure 6B).
We thus reasoned that the preferential expression of antiapop-
totic molecules in TSCM cells could be associated with their preferen-
tial survival. We could not quantify gene expression in antigen-spe-
cific cells due to their paucity. Instead, we sorted “resting” versus 
“blasting” (presumably antigen-responding) CD8+ T cell subsets 
according to their scatter properties (Supplemental Figure 7A). 
The “blasting” lymphocytes uniformly expressed high levels of 
HLA-DR, indicative of activation in vivo (Supplemental Figure 7B). 
Notably, genes such as LEF1 (regulating self-renewal), BCL2, and 
MCL1 (both antiapoptotic) were not differentially expressed among 
“resting” memory subsets, but were specifically upregulated to high 
levels in “blasting” TSCM cells (Supplemental Figure 7C).
In summary, our data show that NHP TSCM cells are closely 
related to human TSCM cells, and constitute a discrete memory 
T cell subset, distinct from TCM cells, on the basis of: (a) surface 
immunophenotype, (b) localization in the body, (c) cytokine pro-
duction, and (d) in vivo turnover. Although TCM cells were demon-
strated to possess stem cell–like properties in multiple experimen-
tal conditions (7), our data suggest that TSCM cells are superior 
to TCM cells in this regard owing to their superior self-renewing 
capability and multipotency, their relative antigen dependence in 
vivo, and their apoptotic refractoriness. Notably, these properties 
are not unique to TSCM cells, but rather are highly preferentially 
associated with the TSCM subset. And importantly, the superior 
persistence of TSCM cells following antigen loss suggests that they 
are the main precursors of T cell memory in the postantigen phase.
Maintenance of antigen-specific TSCM cells is likely intrinsically 
programmed. We exclude the possibility that the TSCM pool is 
maintained by the continuous recruitment of newly generated 
naive T cells by thymic output (15) in our model, as thymic out-
put is severely impaired in chronic, untreated HIV and SIV infec-
tions (16, 17). In addition, we find equivalent maintenance of 
CM9- and TL8-specific TSCM cells despite a profound difference 
in antigen availability.
Our data strongly suggest that TSCM cells play a crucial role in 
supporting long-term cellular immunity in vivo. Future studies 
aimed at identifying antigen-specific TSCM cells in adoptive trans-
fer models are required to define whether they are uniquely suited 
for this function. On the basis of these properties, we propose 
that future vaccination strategies designed to generate durable 
immunity should target the induction of TSCM cells. Nevertheless, 
cellular immunotherapy strategies will need to exploit TSCM prop-
erties to support the persistence of in vivo–transferred virus- and 
tumor-specific T cells.
Methods
Animals. Animals were handled in accordance with the standards of the 
American Association for the Accreditation of Laboratory Animal Care 
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